Journal: Cell proliferation

Article Title: Tetrahedral Framework Nucleic Acid Relieves Sepsis-Induced Intestinal Injury by Regulating M2 Macrophages.

doi: 10.1111/cpr.13803

Figure Lengend Snippet: FIGURE 4 | Treatment of tFNAs activated the Mertk signal pathway. (A) Representative images of immunofluorescent staining for tFNAs (red) and DAPI (blue) in the colon and ileum (Scale bar = 20 μm). (B) Immunohistochemical staining of Mertk in colon (scale bar: 100 μm). (C–F) Western blotting detection of Mertk, p-Mertk, STAT1, p-STAT1, SOCS1, SOCS3 expression in the colon. (G) Quantitative analysis of the protein expression levels. (H) Schematic diagram of the inhibition of Mertk altering macrophage activation by tFNAs. (I–L) Western blotting detection of Mertk, p- Mertk, STAT1, p-STAT1, SOCS1, SOCS3 expression in the colon. (M) Quantitative analysis of the protein expression levels. Data were represented as mean ± SD, *p < 0.05, **p < 0.01.

Article Snippet: The antibody for ZO- 1 was from Wuhan Servicebio; the antibody for occludin was from Abcam; the antibodies for Mer, STAT1, p- STAT1, SOCS1 and SOCS3 were from Cell Signalling Technology; the antibody for p- Mer (Tyr749) was from Thermo Fisher Scientific; and UNC2250 was purchased from MCE.

Techniques: Staining, Immunohistochemical staining, Western Blot, Expressing, Inhibition, Activation Assay

Journal: Viruses

Article Title: ZIKV Strains Elicit Different Inflammatory and Anti-Viral Responses in Microglia Cells

doi: 10.3390/v15061250

Figure Lengend Snippet: Infection of BV2 microglia cells with ZIKV PE243 and ZIKV MR766 strains differentially modulate the pro-inflammatory miRNA-155 and anti-inflammatory and anti-viral factors. BV2 cells were infected with both ZIKV PE243 or ZIKV MR766 , with an MOI of 1, at 12, 24, 48, and 72 hpi using mock-treated (Mock) as a negative control and LPS + ATP (LPS) as a positive control. ( a ) miRNA-155, ( b ) SOCS1, ( d ) SOCS3 and ( e ) SHIP1 mRNA expression levels were measured by RT-qPCR. ∆∆Ct plotted results were normalized to hprt1 and mock values for mRNAs, and U6 and mock for miRNAs. ( c ) The protein SOCS1 expressions were analyzed by Western analysis. The membrane was stained with anti-SOCS1 and anti-β-actin as a loading control. Statistical analysis was performed by One-Way ANOVA, considering * p < 0.05, ** p < 0.01, and *** p < 0.001 as significant differences.

Article Snippet: Primary antibodies against PPAR-γ (Thermo Fisher Scientific Inc., PA3-821A) and SOCS1 (Boster Biological Technology Co. Ltd, Pleasanton, CA, USA, PA1074) were added to the membranes, and then secondary antibodies against mouse (Cell Signaling Technology, 7076S, Danvers, MA, USA) and rabbit (KPL, 04-15-06) were used.

Techniques: Infection, Negative Control, Positive Control, Expressing, Quantitative RT-PCR, Western Blot, Membrane, Staining, Control

Journal: Viruses

Article Title: ZIKV Strains Elicit Different Inflammatory and Anti-Viral Responses in Microglia Cells

doi: 10.3390/v15061250

Figure Lengend Snippet: Comparison of inflammatory, anti-inflammatory, and anti-viral marker expressions by BV2 microglial cell line after infection with Brazilian and African ZIKV strains (ZIKV PE243 and ZIKV MR766 ).

Article Snippet: Primary antibodies against PPAR-γ (Thermo Fisher Scientific Inc., PA3-821A) and SOCS1 (Boster Biological Technology Co. Ltd, Pleasanton, CA, USA, PA1074) were added to the membranes, and then secondary antibodies against mouse (Cell Signaling Technology, 7076S, Danvers, MA, USA) and rabbit (KPL, 04-15-06) were used.

Techniques: Comparison, Marker, Infection

Journal: The Journal of allergy and clinical immunology

Article Title: The Immunology of AD and its Reversibility with Broad Spectrum and Targeted Therapies

doi: 10.1016/j.jaci.2017.01.011

Figure Lengend Snippet: Recent controlled trials in AD CRTH2 Prostaglandin D2 receptor 2; H4R Histamine H4 receptor; JAK Janus kinase; PDE4 Phosphodiesterase 4; TSLP thymic stromal lymphopoietin; TSLPR thymic stromal lymphopoietin receptor;

Article Snippet: Baricitinib , , JAK1/2 , Jak1/2 inhibitor – Oral small molecule , In Phase II , Eli Lilly , NCT02576938.

Techniques:

Journal: Pharmaceutics

Article Title: Emerging Treatments and New Vehicle Formulations for Atopic Dermatitis

doi: 10.3390/pharmaceutics16111425

Figure Lengend Snippet: Topical treatments for AD and their common adverse reactions.

Article Snippet: The understanding of pathophysiological pathways has contributed to the development of innovative therapies, including biological therapies, JAK inhibitors, but also emerging technologies like nanotechnology-based drug delivery systems.

Techniques: